α-Mangostin and Doxorubicin Combination Synergistically Inhibited Cell Growth, Induced Cell Apoptosis with Increased Bak Protein and Decreased FLT3-ITD Phosphorylation in AML MOLM-13 Cell Line
α-Mangostin and Doxorubicin Combination Synergistically Inhibited Cell Growth, Induced Cell Apoptosis with Increased Bak Protein and Decreased FLT3-ITD Phosphorylation in AML MOLM-13 Cell Line
Review Data
Q: Is the topic relevant to the journal area of interest? Is it contemporary and interesting for
researchers?
A: Very good
Abstract & Keywords
Q: Are all required components included in the abstract? Are the keywords appropriately chosen?
A: Excellent
Goal
Q: Is the goal explicitly stated in the Introduction? Is its formulation clear and unambiguous?
A: Very good
Structure
Q: Is the paper's structure coherent? Is it in coherence with the goal of the paper?
A: Good
Tools and Methods
Q: Are methods the author uses adequate and well used?
A: Very good
Discussion & Conclusion
Q: Is it related to the results presented before? Do you consider them as coherent?
A: Very good
Comments:
In this study, α-Mangostin and Dox combined drug blocked the cell cycle in addition to apoptosis induction, contributing to reduction in cell growth. The Discussion puts forth the rationale for taking up the study, effectively describes the relevant literature and enlists the implications of the findings from the present study in that context. The experiments performed are really convincing and the observations are properly explained and discussed in the Discussion section. The study discusses that treatment with two drugs such as Dox and α-Mangostin could enhance efficacy, reduce side effects by lowering the dosage of monotherapy. The Conclusion is apt recommending future research to include known FLT3 inhibitors (for example midostaurin) for comparison study with the combination of Dox and α-Mangostin, to investigate as targeted therapy for FLT3-ITD mutation.
Literature
Q: Does the author utilize relevant literature?
A: Very good
Author's knowledge
Q: What is the level of the author’s knowledge? Does the author utilize all recent contributions relevant to the topic?
A: Very good
Length
Q: Is the length of the paper adequate to the significance of the topic? Do you suggest shortening the paper without losing its value?
A: Good
Figures & Tables
Q: Does the author use them suitably? Are legend and notations clear?
A: Very good
Writing style
Q: Is it clear and understandable?
A: Good
Further comments on the paper
Comments: This study evaluates α-Mangostin and doxorubicin (Dox) singly and in combination, for their anti-leukemic effect on MOLM-13, an acute myeloid leukemia (AML) cell line with FLT3-ITD mutation. Acute myeloid leukemia is an aggressive blood cancer with fast progression and characterised by poor prognosis with treatment failure due to disease relapse. This study holds significance as it reports for the first time a novel in vitro finding that the combination of doxorubicin with α-Mangostin caused an inhibition of FLT3 phosphorylation in the acute myeloid leukemia cell line, MOLM-13. It also reports cell cycle arrest contributed by inhibition of cdc25 phosphatases by the combined drug. Interestingly, in this study, compared to the single drugs, the combined Dox and α-Mangostin showed more Bak protein expression with statistical significance (P<0.05), suggesting a contribution of Bak to the enhanced apoptosis induction by the combined drug.
Q: Would you recommend this manuscript for further publication?
A: Yes - Suitable to be published
If you have any questions and clarifications you can write to the journal.
Thanks,
Science Repository Team
Science Repository This email is restricted to the intended user. |
Science Repository - Support |
Author Info
Cynthia. U. Osemeke Xuesong Wen Hemda Garelick Sandra Appiah
Corresponding Author
Sandra AppiahDepartment of Natural Science, Faculty of Science and Technology, Middlesex University, The Burroughs, London, UK
Article Info
Article Type
Research ArticlePublication history
Received: Fri 23, Jul 2021Accepted: Wed 11, Aug 2021
Published: Mon 30, Aug 2021
Copyright
© 2023 Sandra Appiah. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.DOI: 10.31487/j.COR.2021.08.12